T(8;21) in Blood Cell Proliferation and Differentiation
T(8;21) in Blood Cell Proliferation and Differentiation
批准号:
7283807
负责人:
DONG-ER ZHANG
金额:
$28.93万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2008-02-29
关键词:
AML1-ETO fusion proteinAcute Myelocytic LeukemiaAddressAnimal ModelBlood CellsC-terminalCell Differentiation processCell ProliferationCellsDNA Binding DomainDataDevelopmentGenesGenetically Engineered MouseHematopoiesisHematopoieticKnock-in MouseKnockout MiceMolecularMolecular AbnormalityMutationMyelogenousN-terminalPathway interactionsPlayRUNX1 geneRoleSex ChromosomesTestingTransgenic Miceacute myeloid leukemia 1 proteinembryonic stem cellhuman CBFA2T1 proteinleukemialeukemogenesisresearch studyt(821)(q22q22)
中文摘要
描述(由申请人提供):t(8;21)是急性髓性白血病中最常见的遗传异常之一,占所有病例的15%。这种易位产生融合蛋白AML1-ETO,它包含AML1蛋白的n端区域,包括runt DNA结合域,以及C端几乎整个ETO蛋白。本研究验证了t(8;21)融合蛋白AML1-ETO需要额外突变才能发生白血病的假设,并旨在确定与额外突变相关的分子途径。对AML1敲除小鼠的研究表明,AML1在造血过程中起着关键作用。我们对AML1- eto敲入小鼠的分析表明,AML1- eto在早期造血细胞承诺过程中主要阻断AML1的功能。此外,我们的数据表明AML1-ETO表达并不足以引起白血病。在Specific Aim #1中提出的研究将利用AML1- eto敲入AML1位点的ES细胞来研究AML1- eto对造血细胞承诺的影响。在Specific Aim #2中提出的研究将使用基因工程小鼠研究性染色体在t(8;21)相关急性髓系白血病发展中的作用。在Specific Aim #3中提出的研究将研究转基因小鼠中与t(8;21)急性髓系白血病发生相关的其他基因的异常表达或突变。我们已经建立了AML1-ETO诱导或髓系特异性表达的动物模型。提出的实验将解决有关正常血细胞分化的关键因素以及t(8;21)如何与白血病的发展相关的基本问题。
英文摘要
DESCRIPTION (provided by applicant): The t(8;21) is one of the most common genetic abnormalities in acute myeloid leukemia, identified in 15% of all cases. This translocation generates the fusion protein, AML1-ETO, which contains the N-terminal region of the AML1 protein, including the runt DNA binding domain, and almost the entire ETO protein at the C terminal region. This proposal tests the hypothesis that the t(8;21) fusion protein AML1-ETO requires additional mutations for leukemogenesis and aims to identify molecular pathways associated with the additional mutation. Study of AML1 knockout mice demonstrates that AML1 plays a critical role during hematopoiesis. Our analysis with AML1-ETO knock-in mice shows that AML1-ETO dominantly blocks AML1 function during early hematopoietic cell commitment. Furthermore, our data suggest that AML1-ETO expression is not sufficient to cause leukemia. The studies proposed in Specific Aim #1 will investigate the effect of AML1-ETO on hematopoietic cell commitment using ES cells with AML1-ETO knocked into the AML1 locus. The studies proposed in Specific Aim #2 will study the involvement of sex chromosomes in the development of t(8;21) associated acute myeloid leukemia using genetically engineered mice. The studies proposed in Specific Aim #3 will investigate the abnormal expression or the mutation of additional genes associated with the development of t(8;21) involved acute myeloid leukemia in transgenic mice. We have established animal models with either inducible or myeloid specific expression of AML1-ETO. The experiments proposed will address fundamental questions about the factors critical for normal blood cell differentiation and how t(8;21) is related to the development of leukemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
USP18 in Cancer Development
-
批准号:10596566
-
项目类别:
-
资助金额:$37.09万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
USP18 in Cancer Development
-
批准号:9886213
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
USP18 in Cancer Development
-
批准号:10377534
-
项目类别:
-
资助金额:$37.09万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
USP18 in Cancer Development
-
批准号:10132268
-
项目类别:
-
资助金额:$37.82万
-
财政年份:2019
-
负责人:DONG-ER ZHANG
-
依托单位:
CSF2 receptor mediated actions in t(8;21) leukemia
-
批准号:9014529
-
项目类别:
-
资助金额:$34.49万
-
财政年份:2015
-
负责人:DONG-ER ZHANG
-
依托单位:
CSF2 receptor mediated actions in t(8;21) leukemia
-
批准号:8842430
-
项目类别:
-
资助金额:$34.59万
-
财政年份:2015
-
负责人:DONG-ER ZHANG
-
依托单位:
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
-
批准号:10400021
-
项目类别:
-
资助金额:$62.03万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and protein ISGylation in Cancer
-
批准号:8616739
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and protein ISGylation in Cancer
-
批准号:8535417
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
-
批准号:9922899
-
项目类别:
-
资助金额:$64.18万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and Protein ISGylation in Cancer
-
批准号:10116297
-
项目类别:
-
资助金额:$41.43万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and Protein ISGylation in Cancer
-
批准号:10590733
-
项目类别:
-
资助金额:$40.51万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and protein ISGylation in Cancer
-
批准号:9002027
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
ISG15 and Protein ISGylation in Cancer
-
批准号:10360673
-
项目类别:
-
资助金额:$40.78万
-
财政年份:2013
-
负责人:DONG-ER ZHANG
-
依托单位:
International RUNX Workshop
-
批准号:8129107
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2011
-
负责人:DONG-ER ZHANG
-
依托单位:
SEARCH AML1-ETO INTERACTING PROTEIN
-
批准号:8171272
-
项目类别:
-
资助金额:$0.24万
-
财政年份:2010
-
负责人:DONG-ER ZHANG
-
依托单位:
UBP43 in Hematopoiesis
-
批准号:7919940
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
SEARCH AML1-ETO INTERACTING PROTEIN
-
批准号:7723659
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
UBP43 in Hematopoiesis
-
批准号:8318588
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
UBP43 in Hematopoiesis
-
批准号:7687335
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:DONG-ER ZHANG
-
依托单位:
海外基金